Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC50s between 4 and 5 nM. setrobuvir shows good binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 55,000 |
5 mg | 在庫あり | ¥ 138,000 |
10 mg | 在庫あり | ¥ 196,500 |
25 mg | 在庫あり | ¥ 294,000 |
50 mg | 在庫あり | ¥ 402,000 |
100 mg | 在庫あり | ¥ 542,000 |
500 mg | 在庫あり | ¥ 1,085,500 |
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 178,000 |
説明 | Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC50s between 4 and 5 nM. setrobuvir shows good binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp. |
ターゲット&IC50 | RNA synthesis and primer extension:4~5 nM |
In vivo | Setrobuvir (200, 400, and 800 mg) BID were -2.1, -2.2, and -2.9 log10 IU/mL, respectively (vs ≤0.1 log10 IU/mL with placebo).[3] |
別名 | RO-5466731, ANA-598, RG7790, ANA598, RG-7790 |
分子量 | 560.62 |
分子式 | C25H25FN4O6S2 |
CAS No. | 1071517-39-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.61 mg/mL (10 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Setrobuvir 1071517-39-9 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome SARS-CoV HCV Protease DNA/RNA Synthesis RO5466731 RO-5466731 ANA-598 RG7790 RO 5466731 ANA 598 ANA598 RG-7790 RG 7790 Inhibitor inhibitor inhibit